Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling

Abstract excerpt

PURPOSE: Gastrointestinal stromal tumors (GIST) are characterized by expressing a gain-of-function mutation in KIT, and to a lesser extent, PDGFR. Imatinib mesylate, a tyrosine kinase inhibitor, has activity against GISTs that contain oncogenic mutations of KIT. In this study, KIT and PDGFRalpha mutation status was analyzed and protein modeling approaches were used to assess the potential effect of KIT mutations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal Tumor Research and Treatment
• Share to Sarcoma Diagnosis and Treatment
• Share to Teratomas and Epidermoid Cysts